東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Assessing the cost-effectiveness of ...

Kamal, Khalid M.

Linked to FindBook

Google Book

Amazon

博客來

Assessing the cost-effectiveness of tumor necrosis factor inhibitors and prescribing practices of rheumatologists in patients with rheumatoid arthritis.

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Assessing the cost-effectiveness of tumor necrosis factor inhibitors and prescribing practices of rheumatologists in patients with rheumatoid arthritis./
Author:	Kamal, Khalid M.
Description:	235 p.
Notes:	Chair: S. Suresh Madhavan.
Contained By:	Dissertation Abstracts International66-12B.
Subject:	Health Sciences, Health Care Management. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3201729
ISBN:	9780542470035

Assessing the cost-effectiveness of tumor necrosis factor inhibitors and prescribing practices of rheumatologists in patients with rheumatoid arthritis.
Kamal, Khalid M.

Assessing the cost-effectiveness of tumor necrosis factor inhibitors and prescribing practices of rheumatologists in patients with rheumatoid arthritis. - 235 p.

Chair: S. Suresh Madhavan.

Thesis (Ph.D.)--West Virginia University, 2005.

Three new tumor necrosis factor (TNF) inhibitors, adalimumab, etanercept, and infliximab, have been approved for use in patients with active RA. The goals of the study were two fold: (1) to perform a cost-effectiveness analysis of the three TNF inhibitors in patients with RA that inadequately respond to MTX alone and (2) to assess the current prescribing patterns, laboratory monitoring practices, and perceived barriers of rheumatologists in prescribing these agents in patients with RA. Phase I involved the development of a Markov simulation model to estimate the health effects and costs associated with five treatment strategies in patients with RA that inadequately respond to MTX alone: (1) adalimumab plus MTX, (2) etanercept plus MTX, (3) infliximab plus MTX, (4) leflunomide plus MTX, and (5) standard therapy of MTX. A hypothetical cohort of 10,000 55-year old women was evaluated using Monte Carlo simulation. The study was conducted from a societal perspective. The main outcome measures were net gains in quality-adjusted life expectancy and incremental cost-effectiveness ratios, (ICERs) in dollars per quality adjusted life year (QALY) gained. Costs and effects were discounted at 3%. Etanercept plus MTX was the most cost-effective treatment with an ICER of

ISBN: 9780542470035Subjects--Topical Terms:

1017922
Health Sciences, Health Care Management.

Assessing the cost-effectiveness of tumor necrosis factor inhibitors and prescribing practices of rheumatologists in patients with rheumatoid arthritis.
LDR:03191nam 2200277 a 45 001 965562
005 20110906
008 110906s2005 eng d
020 $a 9780542470035
035 $a (UnM)AAI3201729
035 $a AAI3201729
040 $a UnM $c UnM
100 1 $a Kamal, Khalid M. $3 1288334
245 1 0 $a Assessing the cost-effectiveness of tumor necrosis factor inhibitors and prescribing practices of rheumatologists in patients with rheumatoid arthritis.
300 $a 235 p.
500 $a Chair: S. Suresh Madhavan.
500 $a Source: Dissertation Abstracts International, Volume: 66-12, Section: B, page: 6548.
502 $a Thesis (Ph.D.)--West Virginia University, 2005.
520 $a Three new tumor necrosis factor (TNF) inhibitors, adalimumab, etanercept, and infliximab, have been approved for use in patients with active RA. The goals of the study were two fold: (1) to perform a cost-effectiveness analysis of the three TNF inhibitors in patients with RA that inadequately respond to MTX alone and (2) to assess the current prescribing patterns, laboratory monitoring practices, and perceived barriers of rheumatologists in prescribing these agents in patients with RA. Phase I involved the development of a Markov simulation model to estimate the health effects and costs associated with five treatment strategies in patients with RA that inadequately respond to MTX alone: (1) adalimumab plus MTX, (2) etanercept plus MTX, (3) infliximab plus MTX, (4) leflunomide plus MTX, and (5) standard therapy of MTX. A hypothetical cohort of 10,000 55-year old women was evaluated using Monte Carlo simulation. The study was conducted from a societal perspective. The main outcome measures were net gains in quality-adjusted life expectancy and incremental cost-effectiveness ratios, (ICERs) in dollars per quality adjusted life year (QALY) gained. Costs and effects were discounted at 3%. Etanercept plus MTX was the most cost-effective treatment with an ICER of $4 9,724/QALY. Leflunomide plus MTX was the second most cost-effective option with an ICER of $5 2,833/QALY. One-way and probabilistic sensitivity analyses indicated that the conclusions were relatively stable to variations in model assumptions. In phase II, a survey was mailed to a randomly selected national sample of rheumatologists, of which 22.3% responded. The survey findings indicated that TNF inhibitor use was not restricted to moderate and severe patients with RA. Also, TNF inhibitor plus one disease modifying anti-rheumatic drug was the treatment of choice in patients with severe RA that inadequately respond to MTX alone. Costs to the patient and insurance coverage were perceived as major barriers in prescribing TNF inhibitors. One-fourth of the rheumatologists reported not using any monitoring guidelines for the TNF inhibitors indicating a need to revise monitoring guidelines or perhaps implement new guidelines for TNF inhibitors.
590 $a School code: 0256.
650 4 $a Health Sciences, Health Care Management. $3 1017922
650 4 $a Health Sciences, Pharmacy. $3 1017737
690 $a 0572
690 $a 0769
710 2 0 $a West Virginia University. $3 1017532
773 0 $t Dissertation Abstracts International $g 66-12B.
790 $a 0256
790 1 0 $a Madhavan, S. Suresh, $e advisor
791 $a Ph.D.
792 $a 2005
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3201729